论文部分内容阅读
目的:观察抗CD_3单克隆抗体激活的杀伤细胞(CD_3AK细胞)对恶性肿瘤患者细胞免疫功能的影响。方法:65例恶性肿瘤病人分为两组,实验组(CD_3AK细胞+化疗)35例,对照组(单纯化疗)30例,两组病人分别于治疗前及治疗后作外周血T细胞亚群和血清可溶性白细胞介素2受体(sIL-2R)水平测定。结果:恶性肿瘤病人细胞免疫功能均较正常人低,化疗病人辅以CD_3AK细胞治疗后外周血CD_3~+、CD_4~+ T细胞及CD_4~+/CD_8~+比值均明显升高,sIL-2R水平显著下降;对照组病人经化疗后CD_3~+、CD_4~+ T细胞与CD_4~+/CD_8~+比值明显下降,sIL-2R水平也下降,但其下降幅度比CD_3AK细胞治疗组小,两者比较有统计学意义(P<0.05)。结论:CD_3AK细胞能有效地提高化疗中恶性肿瘤患者的细胞免疫功能。
Objective: To observe the effect of anti-CD_3 monoclonal antibody-activated killer cells (CD_3AK cells) on cellular immune function in patients with malignant tumors. Methods: Thirty-five patients with malignant tumor were divided into two groups: 35 cases in the experimental group (CD 3AK cells + chemotherapy) and 30 cases in the control group (chemotherapy alone) .Two groups of patients were divided into T cell subsets and peripheral blood before and after treatment Serum soluble interleukin 2 receptor (sIL-2R) levels were measured. Results: The cell immune function of patients with malignant tumor was lower than that of normal people. The ratio of CD_3 ~ +, CD_4 ~ + T cells and CD_4 ~ + / CD_8 ~ + in peripheral blood of patients with chemotherapy were significantly increased after treatment with CD_3AK cells. The levels of CD_3 ~ +, CD_4 ~ + T cells and CD_4 ~ + / CD_8 ~ + in the control group decreased significantly and the sIL-2R level decreased after chemotherapy, but the decrease was smaller than that of CD_3AK cells Who were statistically significant (P <0.05). Conclusion: CD_3AK cells can effectively improve the cellular immune function of malignant tumor patients under chemotherapy.